دورية أكاديمية
أعرض في EDS

Antigens Expressed by Breast Cancer Cells Undergoing EMT Stimulate Cytotoxic CD8 + T Cell Immunity.

التفاصيل البيبلوغرافية
العنوان: Antigens Expressed by Breast Cancer Cells Undergoing EMT Stimulate Cytotoxic CD8 + T Cell Immunity.
المؤلفون: Camp FA; Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO 80045, USA., Brunetti TM; Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO 80045, USA., Williams MM; Department of Pathology, University of Colorado School of Medicine, Aurora, CO 80045, USA., Christenson JL; Department of Pathology, University of Colorado School of Medicine, Aurora, CO 80045, USA., Sreekanth V; Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045, USA., Costello JC; Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045, USA., Hay ZLZ; Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO 80045, USA., Kedl RM; Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO 80045, USA., Richer JK; Department of Pathology, University of Colorado School of Medicine, Aurora, CO 80045, USA., Slansky JE; Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
المصدر: Cancers [Cancers (Basel)] 2022 Sep 09; Vol. 14 (18). Date of Electronic Publication: 2022 Sep 09.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Antigenic differences formed by alterations in gene expression and alternative splicing are predicted in breast cancer cells undergoing epithelial to mesenchymal transition (EMT) and the reverse plasticity known as MET. How these antigenic differences impact immune interactions and the degree to which they can be exploited to enhance immune responses against mesenchymal cells is not fully understood. We utilized a master microRNA regulator of EMT to alter mesenchymal-like EO771 mammary carcinoma cells to a more epithelial phenotype. A computational approach was used to identify neoantigens derived from the resultant differentially expressed somatic variants (SNV) and alternative splicing events (neojunctions). Using whole cell vaccines and peptide-based vaccines, we find superior cytotoxicity against the more-epithelial cells and explore the potential of neojunction-derived antigens to elicit T cell responses through experiments designed to validate the computationally predicted neoantigens. Overall, results identify EMT-associated splicing factors common to both mouse and human breast cancer cells as well as immunogenic SNV- and neojunction-derived neoantigens in mammary carcinoma cells.
References: Genome Biol. 2016 Jun 06;17(1):122. (PMID: 27268795)
NPJ Breast Cancer. 2021 May 27;7(1):64. (PMID: 34045467)
Genes Dev. 2008 Apr 1;22(7):894-907. (PMID: 18381893)
Genes (Basel). 2014 Sep 11;5(3):804-20. (PMID: 25216122)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
PLoS Genet. 2011 Aug;7(8):e1002218. (PMID: 21876675)
Sci Rep. 2021 Jun 30;11(1):13590. (PMID: 34193879)
Pharmaceuticals (Basel). 2021 Sep 29;14(10):. (PMID: 34681217)
J Immunol. 2016 Aug 1;197(3):691-8. (PMID: 27431984)
Anticancer Res. 2005 Nov-Dec;25(6B):3905-15. (PMID: 16312045)
Front Oncol. 2022 Mar 21;12:786438. (PMID: 35387130)
Bioinformatics. 2009 Jul 15;25(14):1754-60. (PMID: 19451168)
Science. 2018 Mar 23;359(6382):1355-1360. (PMID: 29567706)
J Immunol. 1996 Apr 15;156(8):2909-17. (PMID: 8609411)
JNCI Cancer Spectr. 2018 Nov;2(4):pky062. (PMID: 30627694)
Crit Rev Oncog. 2013;18(1-2):43-73. (PMID: 23237552)
Cancer Hallm. 2013 Mar;1(1):38-49. (PMID: 24611128)
Cancer Biol Ther. 2010 Aug 1;10(3):219-22. (PMID: 20592490)
Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6575-9. (PMID: 1650475)
Front Mol Biosci. 2020 Apr 24;7:72. (PMID: 32391382)
J Clin Med. 2016 Jan 26;5(2):. (PMID: 26821054)
Cell Cycle. 2009 Mar 15;8(6):843-52. (PMID: 19221491)
Protein Sci. 2003 May;12(5):1007-17. (PMID: 12717023)
Clin Cancer Res. 2016 Feb 1;22(3):609-20. (PMID: 26420858)
Nat Biotechnol. 2019 Aug;37(8):907-915. (PMID: 31375807)
Elife. 2016 May 25;5:. (PMID: 27223325)
Nat Genet. 2014 Aug;46(8):912-918. (PMID: 25017105)
Breast Cancer Res. 2011 Apr 18;13(2):R45. (PMID: 21501518)
Cancer Cell. 2018 Aug 13;34(2):211-224.e6. (PMID: 30078747)
Nat Commun. 2014 Aug 19;5:4674. (PMID: 25135627)
Wellcome Open Res. 2017 Jan 17;2:6. (PMID: 28239666)
Dis Model Mech. 2015 Mar;8(3):237-51. (PMID: 25633981)
Cancer Res. 2017 Aug 1;77(15):3982-3989. (PMID: 28428275)
Gigascience. 2021 Feb 16;10(2):. (PMID: 33590861)
Bioinformatics. 2015 Jul 1;31(13):2202-4. (PMID: 25701572)
Nat Commun. 2022 May 19;13(1):2791. (PMID: 35589755)
Comput Struct Biotechnol J. 2021 Jun 17;19:3842-3851. (PMID: 34306571)
Cell Syst. 2015 Dec 23;1(6):417-425. (PMID: 26771021)
Mol Cancer Res. 2019 Jan;17(1):30-41. (PMID: 30213797)
Nature. 2017 Jul 5;547(7661):E1-E3. (PMID: 28682326)
Pharmacol Ther. 2019 Feb;194:161-184. (PMID: 30268772)
Nat Biotechnol. 2018 Dec;36(11):1056-1058. (PMID: 30114007)
BMC Cancer. 2019 Nov 12;19(1):1091. (PMID: 31718602)
Breast Care (Basel). 2019 Dec;14(6):344-353. (PMID: 31933579)
Nat Biotechnol. 2011 Jan;29(1):24-6. (PMID: 21221095)
J Immunol. 2017 Nov 1;199(9):3360-3368. (PMID: 28978689)
Br J Cancer. 2021 Jan;124(1):13-26. (PMID: 33239679)
Semin Cell Dev Biol. 2008 Jun;19(3):294-308. (PMID: 18343170)
Nat Cell Biol. 2008 May;10(5):593-601. (PMID: 18376396)
Genome Biol. 2013 Apr 25;14(4):R36. (PMID: 23618408)
Elife. 2015 Sep 15;4:. (PMID: 26371508)
Breast Cancer Res. 2017 Jun 21;19(1):73. (PMID: 28637482)
Bioinformatics. 2016 Jun 15;32(12):1840-7. (PMID: 26873928)
Bioinformatics. 2009 Aug 15;25(16):2078-9. (PMID: 19505943)
J Exp Med. 2004 Mar 15;199(6):775-84. (PMID: 15007094)
Nat Methods. 2017 Apr;14(4):417-419. (PMID: 28263959)
Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1108-13. (PMID: 24390540)
J Mol Cell Biol. 2019 Oct 25;11(10):920-929. (PMID: 31065692)
Int J Womens Health. 2012;4:511-20. (PMID: 23071421)
J Clin Invest. 2009 Jun;119(6):1417-9. (PMID: 19487817)
Nat Immunol. 2019 May;20(5):652-662. (PMID: 30858620)
معلومات مُعتمدة: T32 CA190216 United States CA NCI NIH HHS; CA226879 United States CA NCI NIH HHS; P30 CA046934 United States CA NCI NIH HHS; R01 CA226879 United States CA NCI NIH HHS; P30CA046934 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: CD8+ T cells; epithelial-to-mesenchymal transition (EMT); intron retention; mIR-200c; neoantigen; neojunction; peptide vaccines; whole cell vaccines
تواريخ الأحداث: Date Created: 20220923 Latest Revision: 20230527
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9496737
DOI: 10.3390/cancers14184397
PMID: 36139558
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers14184397